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old Cardioplegia
or Acute Infarction
Viable Adjunct to
eperfusion Therapy?*
illiam Wijns, MD, PHD, FESC,
uy R. Heyndrickx, MD, PHD
alst, Belgium
ince antiquity, the myth of being able to freeze the course
f time and perpetuate life has haunted human minds. The
dea does make sense because life is biochemistry, and
iochemical reactions are exquisitely sensitive to tempera-
ure: slowing down when temperature declines and the
pposite when temperature increases. Nature itself has
uccessfully taken advantage of the conservative capabilities
f cooling, the most advanced and sophisticated protective
echanisms being found in hibernating animals. In contrast
ith non-hibernating animals, where hypothermia is asso-
iated with severe arrhythmias and contractile arrest, hiber-
ating animals exhibit remarkable tolerance and resistance
o these environmental stresses. Hibernation induces adap-
ive changes in Ca2 handling of myocytes whereby the
See page 250
ontractile force remains preserved (1). In the late 1970s,
ahimtoola (2) used the metaphor of hibernation to explain
he adaptive contractile mechanisms operating during
hronic myocardial ischemia. Whether or not these chronic
hanges, including structural abnormalities, which at best
re only partially reversible upon revascularization (3), truly
epresent some form of hibernation remains elusive. How-
ver, during acute conditions, cooling already has received
any applications in clinical medicine among which are
rgan preservation for transplantation, myocardial protec-
ion during cardiac surgery, or neuroprotection during
schemic stroke or cardiac arrest. The present study by
take et al. (4) in this issue of the Journal examines again
he possibility that controlled regional hypothermia might
e a useful adjunct to reperfusion therapy for ST-segment
levation myocardial infarction (STEMI).
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or thed
merican College of Cardiology.
From the Cardiovascular Center Aalst, Aalst, Belgium.s There An Unmet Need?
es, there is. Although reperfusion therapy has considerably
mproved patient outcome after STEMI, the optimal mo-
alities of reperfusion remain under investigation. Even
hough there is evidence that mechanical reperfusion by
irect percutaneous intervention is superior to pharmaco-
ogically induced fibrinolysis, treatment delays or unavail-
bility with either therapy continues to prevent significant
yocardial salvage (“infarct size reduction”) to occur, and
eperfusion in itself causes additional damage, largely
hrough oxidative stress. In the future, depending on avail-
ble resources, the most promising scenario may involve
re-hospital care of STEMI, perhaps using a combined
harmacomechanical approach. Thus, there remains a need
or adjunctive therapy both prior to reperfusion in order to
ncrease the tolerance to ischemia and during reperfusion in
rder to limit reperfusion damage. However, any adjunctive
herapy of value will have to be compatible with each of
hese possible reperfusion scenarios.
atheter-Based Transcoronary Hypothermia
n the first part of this pre-clinical study, which was
erformed in open-chested pigs, Otake et al. (4) have
tudied the effect of reducing the local intramyocardial
emperature by some 3°C while coronary artery occlusion
as maintained. As compared with a control group
eceiving the same volume (2.5 ml/min) of normothermic
aline, infarct sizes were significantly reduced by an
mpressive 75%, as clearly shown by the Reimer (5) plot
f necrotic versus risk area (Fig. 7 of their study). Other
ndexes were significantly improved, including reduced
ate of arrhythmias, increased left ventricular dP/dt max,
aintained coronary flow velocity reserve, and reduced
iomarker release.
In the second part of the study, hypothermic saline
8 ml/min) was delivered at the time of reperfusion. As
ompared with a control group receiving no intracoronary
nfusion, no significant changes were observed in the in-
exes related to infarct size. The flow velocity reserve was
mproved at 60 min (but no longer at 180 min), and the
elease of isoprostans was decreased, as a marker of reduced
xidative stress.
A detailed analysis of Figure 1 in the study by Otake et al.
4) reveals that the time required to reach the desired
yocardial hypothermia varies from 20 to 40 min after
tarting the infusion, presumably depending on the inter-
lay between flow rates of the infusion and the coronary
ow. Most interestingly, when reperfusion was restored in
tudy 1, the myocardial temperature returned to baseline
alues despite continued infusion of hypothermic saline at
he rate of 2.5 ml/min. This finding has prompted the use
f higher flow rates in Study 2, allowing for a faster
chievement and maintenance of the desired temperature
ecrease, despite ongoing reperfusion.
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Editorial Comment January 16, 2007:261–2Because intracoronary flow rates had to be increased up to
t least twice the normal baseline coronary flow, as can be
stimated from the size of the risk area of the left ventricle,
he authors have verified that no excessive edema resulted.
lthough this represents a worthwhile finding, the authors
ave introduced a flaw in the design of Study 2. Indeed, the
ontrol group of animals did not receive any coronary
nfusion. Strictly speaking, one cannot exclude that the
ntracoronary infusion of normothermic saline could have
imilar beneficial effects on indexes of microcirculatory
unction than those observed with hypothermia. Indeed, in
he presence of angiographic no-reflow, increasing coronary
ow by infusion of adenosine or other vasoactive agents was
hown beneficial (6).
otential Clinical Relevance
rior clinical studies on the effect of cooling during reper-
usion treatment of STEMI have failed to show significant
enefit (7). Limitations of the therapy were related to
hivering and systemic effects of reducing total body tem-
erature. Targeted approaches to the myocardium have only
een tested in animal models and require access to the
ericardium (8). Although feasible, this approach entails an
dditional invasive procedure that exposes the already
cutely ill patient to incremental treatment-related risks.
herefore, the use of a catheter-based transcoronary ap-
roach would seem extremely appealing, in particular in
atients already submitted to mechanical reperfusion in
hom invasive procedures are performed on a routine basis.
lso, the current approach was demonstrated not to cause
ny changes in core body temperature. Thus, from an
nstrumental viewpoint, catheter-based transcoronary hypo-
hermia as proposed by Otake et al. (4) seems like a
otentially useful adjunct to reperfusion therapy for
TEMI.
However, the key question remains whether the current
re-clinical data are robust enough to support early trans-
ation in the clinic. The most impressive results were
btained in Study protocol 1, which provides strong proof of
oncept but unfortunately is not relevant to clinical practice.
atheter-based transcoronary hypothermia obviously re-
uires invasive access to the coronaries, under which cir-
umstances coronary occlusion will not be maintained for 60
in (Fig. 1 in Otake et al. [4]). Study protocol 2 is more
elevant to the practice of direct percutaneous coronary
ntervention, but paradoxically, the observed results of
ypothermic coronary perfusion are modest, limited to
inor microcirculatory changes, and perhaps obtainable
ith infusion of normothermic saline (not tested). As to the
arge number of patients treated either with systemic fibri-
olysis or in the future during the pre-hospital phase of
TEMI, catheter access will not be available, and other
pproaches than the currently proposed transcoronary de-
ivery of cold saline will be required.ummary and Future Investigations
he current study by Otake et al. (4) adds further evidence
o the available data that support the strong cardioprotective
ffect of myocardial cooling, when applied during coronary
cclusion and evolving myocardial infarction. The issue
emains whether cardioprotection will be maintained with
eperfusion and, if so, by which means selective myocardial
ooling will be achievable in the various possible reperfusion
cenarios. Of paramount importance and not addressed in
he study by Otake et al. (4) is the understanding of the
nderlying mechanisms. As indirectly demonstrated, one of
he protective actions of cooling is probably mediated by a
eduction in the oxidative stress. To what extent hypother-
ia also suppresses the inflammatory response during reper-
usion, as was shown in models of ischemia-reperfusion in
ther organs (9), remains to be investigated.
The current approach could easily be combined with
irect percutaneous coronary intervention. However, further
ositive pre-clinical studies will be required before the
otential role of the proposed catheter-based transcoronary
ypothermia can be formally tested as an adjunctive therapy
o reperfusion in patients with STEMI. It is highly desirable
hat these future studies are designed as to mimic as closely
s possible the clinical scene.
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